Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 12/20 | 0.38 |
| ▸ | BACE1 | P56817 | 14/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 10/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3506174 | 0.95 | BACE1 (0.38) | CTSDBACE1BACE2CYP3A4 | |
| SCHEMBL3508650 | 0.95 | BACE1 (0.38) | CTSDBACE1BACE2CYP3A4 | |
| SCHEMBL3511116 | 0.92 | BACE1 (0.43) | CTSDBACE1BACE2CYP3A4 | |
| SCHEMBL3510227 | 0.91 | BACE1 (0.38) | CTSDBACE1BACE2CYP3A4 | |
| SCHEMBL3510767 | 0.90 | BACE1 (0.39) | CTSDBACE1BACE2CYP3A4 | |
| SCHEMBL3509906 | 0.89 | BACE1 (0.39) | CTSDBACE1BACE2CYP3A4 | |
| SCHEMBL3509428 | 0.89 | BACE1 (0.39) | CTSDBACE1BACE2CYP3A4 | |
| SCHEMBL3512076 | 0.88 | BACE1 (0.46) | CTSDBACE1BACE2CYP3A4 | |
| SCHEMBL3506932 | 0.88 | BACE1 (0.40) | CTSDBACE1BACE2CYP3A4 | |
| SCHEMBL3512769 | 0.88 | BACE1 (0.40) | CTSDBACE1BACE2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | claimed |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | CTSD 191/4885BACE1 1/4885BACE2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.